Autopsy report · NCT00360308

Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

“Study stopped due to lack of efficacy.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 1 year 5 months before it stopped.
• 723 participants enrolled.
• Results were posted on the registry 4 years 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Eisai Limited

Sponsor type

Industry

Conditions

Parkinson's Disease

Interventions

Placebo; E2007; E2007

Participants

723

Sites

1

Countries

France

Trials that died the same way

• A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression
  “Study stopped due to lack of efficacy \& funding.” (95% match in meaning)
• Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
  “The study was terminated due to lack of efficacy.” (91% match in meaning)
• A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  “The study was early terminated due to lack of efficacy.” (91% match in meaning)
• Dasatinib in Polycythemia Vera
  “This study was terminated due to lack of efficacy.” (91% match in meaning)
• A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
  “This study was terminated due to a lack of efficacy.” (90% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.